<DOC>
	<DOCNO>NCT00625443</DOCNO>
	<brief_summary>The purpose study determine safety efficacy AKR-501 administer patient chronic Idiopathic Thrombocytopenic Purpura ( ITP ) enrol complete 28 day study treatment Protocol 501-CL-003 .</brief_summary>
	<brief_title>Phase 2 , Parallel Group , Rollover Study AKR-501 Patients With ChronicITP Who Completed 28 Days Study Treatment Protocol 501-CL-003</brief_title>
	<detailed_description>Patients eligible enroll rollover protocol begin study treatment within 2-5 day Day 28 study termination visit Protocol 501-CL-003 . Patients meet primary efficacy response criterion Protocol 501-CL-003 continue receive study treatment assign previous protocol double-blinded manner , one follow 5 treatment : - AKR-501 2.5 mg daily - AKR-501 5 mg daily - AKR-501 10 mg daily - AKR-501 20 mg daily - Placebo Patients meet primary efficacy response criterion Protocol 501-CL-003 otherwise meet eligibility criterion rollover protocol offer open label AKR-501 10 mg daily . This parallel group , rollover study .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>1 . Patients complete 28 day study treatment Protocol 501CL003 . 2 . No significant safety tolerability concern patient 's participation Protocol 501CL003 determine Investigator . 3 . Received medical monitor approval enrollment study . 4 . Patients receive maintenance corticosteroid may enrol , long corticosteroid administer stable dose Investigator foresee need change steroid dose study participation . Patients remain stable corticosteroid dose study participation . 5 . Women childbearing potential must negative serum pregnancy test Day 28 assessment Protocol 501CL003 . ( Childbearing potential define woman surgically sterilize premenopausal perimenopausal i.e. , menstrual flow within 12 month Screening Visit A Protocol 501CL003 ) . 6 . Women childbearing potential must agree practice medically approve form contraception ( one follow must use : condom ( male female ) spermicidal agent , diaphragm cervical cap spermicidal agent , IUD , hormonal contraception , abstinence ) . 7 . Willing able provide write informed consent . 1 . Women pregnant and/or lactating . 2 . Use follow drug treatment : Rituximab Azathioprine , Cyclosporine A , immunosuppressant therapy Aspirin , Aspirincontaining compound , Salicylates , Anticoagulants , Nonsteroidal antiinflammatory drug ( NSAIDs ) ( include Cyclooxygenase2 [ COX2 ] specific NSAIDs ) , clopidogrel ; ticlopidine ; drug affect platelet function . Danazol Rh0 ( D ) immune globulin ( WinRhoÂ® ) intravenous immunoglobulin ( IVIG ) . 3 . Inability comply protocol requirement give informed consent , determine Investigator . For information regard inclusion/exclusion criterion , please see record AKR 501CL003 Protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>ITP</keyword>
	<keyword>Chronic Idiopathic Thrombocytopenic Purpura</keyword>
</DOC>